Pipeline of Type 2 Diabetes Market Review H2 2015 with 192 Companies

ReportsnReports adds Type 2 Diabetes Market research to its database.

This report provides comprehensive information on the therapeutic development for Multiple Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Sclerosis and special features on late-stage and discontinued projects.

Get discount on this research report at http://www.reportsnreports.com/contacts/Discount.aspx?name=468266 .

Companies discussed in this research report are 3SBio Inc., Addex Therapeutics Ltd, Adocia, Advinus Therapeutics Ltd., Aegis Therapeutics, LLC, AFFiRiS AG, Alchemia Limited, Alize Pharma SAS, AlphaMab Co., Ltd, Amarantus Bioscience Holdings, Inc., Ambrx, Inc., Amgen Inc., Anchor Therapeutics, Inc., AntriaBio, Inc., Aphios Corporation, Araim Pharmaceuticals Inc., Arisaph Pharmaceuticals, Inc., ArisGen SA, Array BioPharma Inc., Arrien Pharmaceuticals, LLC, Artery Therapeutics, Inc., Astellas Pharma Inc., AstraZeneca Plc, AUS Bio Limited, Avaxia Biologics, Inc., Bayer AG, Beta-Cell NV, Betagenon AB, Biocon Limited, Biodel Inc., Biogenomics Limited, BioLingus AG, BioRestorative Therapies, Inc., BioTherapeutics Inc., BioTime, Inc., Boehringer Ingelheim GmbH, Boston Therapeutics, Inc., Braasch Biotech LLC, Bristol-Myers Squibb Company, C4X Discovery Limited, Caldan Therapeutics Limited, Cardax Pharmaceuticals, Inc., Cardiolynx AG, Carlina Technologies SAS, Carmot Therapeutics, Inc., Catabasis Pharmaceuticals, Inc., Celon Pharma Sp. z o.o., ChemoCentryx, Inc., Chipscreen Biosciences Ltd, Chong Kun Dang Pharmaceutical Corp., CJ HealthCare Corp., CohBar, Inc., Connexios Life Sciences Pvt. Ltd., CSL Limited, CureDM, Inc., CymaBay Therapeutics, Inc., Daewoong Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, Dance Biopharm Inc., Debiopharm International S.A., Delpor, Inc., Diabetica Limited, Diabetology (Products) Ltd, DiaMedica Inc., Diasome Pharmaceuticals, Inc., DiscoveryBiomed, Inc., Dong-A Socio Group, Eisai Co., Ltd., Elcelyx Therapeutics, Inc., Eli Lilly and Company, enGene, Inc, Enzo Biochem, Inc., Epichem Pty Ltd, Esperion Therapeutics, Inc., Euroscreen S.A., Evotec AG, F. Hoffmann-La Roche Ltd., FibroStatin SL, Flamel Technologies S.A., Foresee Pharmaceuticals, LLC, Generex Biotechnology Corporation, Genfit SA, Genovate Biotechnology Co., LTD., GlaxoSmithKline Plc 229, Glide Pharmaceutical Technologies Limited, Glucox Biotech AB, Gubra ApS, GW Pharmaceuticals Plc, Hadasit Medical Research Services & Development Ltd, Halozyme Therapeutics, Inc., HanAll Biopharma Co., Ltd., Handok Inc., Hanmi Pharmaceuticals, Co. Ltd., Heptares Therapeutics Limited, Hua Medicine Ltd., Hyundai Pharmaceutical Co., Ltd., Innopharmax Inc., Insusense Therapeutics ApS, Intarcia Therapeutics, Inc., Integral Molecular, Inc., IntelliCell BioSciences Inc., Intercept Pharmaceuticals, Inc., Intrexon Corporation, Ionis Pharmaceuticals, Inc., IPCA Laboratories Limited, Islet Sciences, Inc., iTherX, Inc., Japan Tobacco Inc., Jeil Pharmaceutical Co., Ltd., Jenrin Discovery, Inc., Jiangsu Hengrui Medicine Co., Ltd., Johnson & Johnson, Kadimastem Ltd., Kadmon Corporation, LLC, Kainos Medicine, Inc., Kareus Therapeutics, SA, Kissei Pharmaceutical Co., Ltd., Lexicon Pharmaceuticals, Inc., LG Life Science LTD., Ligand Pharmaceuticals, Inc., Lonestar Heart, Inc., Longevity Biotech, Inc, Magnus Life Science, Medesis Pharma S.A., Medestea Research & Production S.p.A., MedImmune, LLC, Mellitech SAS, Merck & Co., Inc., Mesoblast Limited, Metabolic Solutions Development Company, LLC, Metabolys S.A.S., MI.TO. Technology S.r.L., MicroBiome Therapeutics LLC, MidaSol Therapeutics LP, Mitsubishi Tanabe Pharma Corporation, Naia Limited, NatureWise Biotech & Medicals Corporation, NeoPharm Co., Ltd., Neurimmune Holding AG, Neurocrine Biosciences, Inc., NGM Biopharmaceuticals, Inc., Nimbus Therapeutics, LLC, NOD Pharmaceuticals, Inc., Nordic Bioscience A/S, Novartis AG, Novo Nordisk A/S, Noxxon Pharma AG, Omeros Corporation, OPKO Health, Inc., Oramed Pharmaceuticals, Inc., Orbis Biosciences, Inc., Orchid Chemicals & Pharmaceuticals Ltd, Orgenesis, Inc., Panacea Biotec Limited, Paras Biopharmaceuticals Finland Oy, Peptron, Inc., Pfizer Inc., PharmaIN Corporation, Pharnext SAS, PhaseBio Pharmaceuticals, Inc., Poxel SA, Progen Pharmaceuticals Limited, Prometheon Pharma, LLC, ProMetic Life Sciences Inc., ProteoTech, Inc., Prothena Corporation Plc, Purzer Pharmaceutical Co., Ltd., Quantum Pharmaceuticals, Reata Pharmaceuticals, Inc., Receptos, Inc., Red Glead Discovery AB, Regeneron Pharmaceuticals, Inc., reMYND NV, Rhizen Pharmaceuticals S.A., Rhythm Pharmaceuticals, Inc., Saniona AB, Sanofi, Sanwa Kagaku Kenkyusho Co., Ltd., SATT Conectus Alsace SAS, SBI Pharmaceuticals Co., Ltd., Seres Therapeutics, Inc., Serodus ASA, Serometrix, LLC, Sevion Therapeutics, Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Shanghai Pharmaceutical Co., Ltd., Shantani Proteome Analytics Pvt. Ltd., Shionogi & Co., Ltd., Sihuan Pharmaceutical Holdings Group Ltd., Sirona Biochem Corp, SJT Molecular Research, S.L. and SK Chemicals Co., Ltd.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete research report of 1335 pages with TOC is available at http://www.reportsnreports.com/reports/468266-type-2-diabetes-pipeline-review-h2-2015.html .

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


• The report provides a snapshot of the global therapeutic landscape of Multiple Sclerosis
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Multiple Sclerosis and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Multiple Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Multiple Sclerosis pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Contact Info:
Name: Ritesh Tiwari
Email: Send Email
Organization: ReportsandReports
Address: UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune, Maharashtra 411013, India
Phone: +1888 391 54 41
Website: http://www.reportsnreports.com/

Release ID: 105980